Targeting PIK3CA and CDKN2A alterations in Esophageal Adenocarcinoma with Alpelisib and Palbociclib

被引：0
|
作者：
Rustgi, Naryan
Ryan, Thomas
Cho, Jin
Moy, Ryan
Yoon, Sam
Ryeom, Sandra
Yoon, Changhwan
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-C157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C157
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer
    Bartels, Stephan
    van Luttikhuizen, Jana Lisa
    Christgen, Matthias
    Maegel, Lavinia
    Luft, Angelina
    Haenzelmann, Sonja
    Lehmann, Ulrich
    Schlegelberger, Brigitte
    Leo, Fabian
    Steinemann, Doris
    Kreipe, Hans
    JOURNAL OF PATHOLOGY, 2018, 245 (03): : 373 - 383
  • [2] Targeting PIK3CA pathway
    Baselga, J.
    BREAST, 2015, 24 : S10 - S10
  • [3] Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
    Hyman, David M.
    Tran, Ben
    Paz-Ares, Luis
    Machiels, Jean-Pascal
    Schellens, Jan H.
    Bedard, Philippe L.
    Campone, Mario
    Cassier, Philippe A.
    Sarantopoulos, John
    Vaishampayan, Ulka
    Chugh, Rashmi
    Mahipal, Amit
    Lockhart, A. Craig
    Sessa, Cristiana
    Zander, Thomas
    Ng, Matthew
    Curigliano, Giuseppe
    Bendiske, Jennifer
    Chen, Xueying
    Choudhury, Somesh
    Graus-Porta, Diana
    Lewis, Nancy
    Perez Garcia, Jose Manuel
    Jose de Miguel-Luken, Maria
    JCO PRECISION ONCOLOGY, 2019, 3
  • [4] Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma
    Januszewski, A.
    Zhang, Y. Z.
    Brambilla, C.
    Chang, W.
    Laggner, U.
    Bowman, A.
    Adefila-Ideozu, T.
    Vivanco, I.
    Cookson, W.
    Moffatt, M.
    Nicholson, A.
    Popat, S.
    Bowcock, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S465 - S466
  • [5] Treatment of a Patient with PIK3CA mutant metastatic Porocarcinoma with Alpelisib and Radiotherapy
    Horbruegger, M.
    Lenz, F. S.
    Franke, I.
    Tueting, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 6 - 6
  • [6] PIK3CA mutations in small bowel adenocarcinoma
    Shenoy, Santosh
    TUMORI JOURNAL, 2015, 101 (03): : E85 - E87
  • [7] Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions
    Delmonico, Lucas
    Silva Magalhaes Costa, Mauricio Augusto
    Fournier, Marcia Vasconcellos
    Romano, Sergio de Oliveira
    do Nascimento, Cristina Moreira
    Barbosa, Andreia Soares
    Moreira, Aline dos Santos
    Scherrer, Luciano Rios
    Faria Ornellas, Maria Helena
    Alves, Gilda
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2019, 39 : 30 - 35
  • [8] PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis
    Essakly, Ahlem
    Loeser, Heike
    Kraemer, Max
    Alakus, Hakan
    Chon, Seung-Hun
    Zander, Thomas
    Buettner, Reinhard
    Hillmer, Axel M.
    Bruns, Christiane J.
    Schroeder, Wolfgang
    Gebauer, Florian
    Quaas, Alexander
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 157 - 164
  • [9] South West Regional Experience of Alpelisib and Fulvestrant in Patients with a PIK3CA Mutation
    Crocker, C.
    Mckeon, J.
    Dacie, R.
    Amaya, M.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E108 - E109
  • [10] PIK3CA mutations in pancreatic ductal adenocarcinoma (PDAC)
    Pitiyarachchi, O.
    Sim, H-W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1499 - S1499
12345